Advanced Glycation End Products and Receptor (RAGE) Promote Wound Healing of Human Corneal Epithelial Cells.
Cell Line
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
Cells, Cultured
Connexin 43
/ genetics
Corneal Injuries
/ pathology
Dose-Response Relationship, Drug
Epithelial Cells
/ drug effects
Epithelium, Corneal
/ cytology
Glycation End Products, Advanced
/ administration & dosage
HMGB1 Protein
/ administration & dosage
Humans
NF-kappa B
/ metabolism
RNA, Messenger
/ genetics
RNA, Small Interfering
/ genetics
Receptor for Advanced Glycation End Products
/ genetics
Signal Transduction
/ physiology
Wound Healing
/ drug effects
Journal
Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701
Informations de publication
Date de publication:
09 03 2020
09 03 2020
Historique:
entrez:
17
3
2020
pubmed:
17
3
2020
medline:
1
7
2020
Statut:
ppublish
Résumé
We used a human corneal epithelial cell (HCE) line to determine the involvement of the advanced glycation end products (AGEs) / receptor for AGEs (RAGE) couple in corneal epithelium wound healing. After wounding, HCE cells were exposed to two major RAGE ligands (HMGB1 and AGEs), and wound healing was evaluated using the in vitro scratch assay. Following wound healing, the HCE cells were used to study the influence of the RAGE ligands on HCE proliferation, invasion, and migration. Activation of the nuclear factor (NF)-κB signaling pathway by the AGEs/RAGE couple was tested using a luciferase reporter assay. Functional transcriptional regulation by this pathway was confirmed by quantification of expression of the connexin 43 target gene. For each experiment, specific RAGE involvement was confirmed by small interfering RNA treatments. AGEs treatment at a dose of 100 µg/mL significantly improved the wound healing process in a RAGE-dependent manner by promoting cell migration, whereas HMGB1 had no effect. No significant influence of the AGEs/RAGE couple was observed on cell proliferation and invasion. However, this treatment induced an early activation of the NF-κB pathway and positively regulated the expression of the target gene, connexin 43, at both the mRNA and protein levels. Our results demonstrate that the RAGE pathway is activated by AGEs treatment and is involved in the promotion of corneal epithelial wound healing. This positive action is observed only during the early stages of wound healing, as illustrated by the quick activation of the NF-κB pathway and induction of connexin 43 expression.
Identifiants
pubmed: 32176265
pii: 2763126
doi: 10.1167/iovs.61.3.14
pmc: PMC7401750
doi:
Substances chimiques
AGER protein, human
0
Connexin 43
0
Glycation End Products, Advanced
0
HMGB1 Protein
0
HMGB1 protein, human
0
NF-kappa B
0
RNA, Messenger
0
RNA, Small Interfering
0
Receptor for Advanced Glycation End Products
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14Références
J Inflamm (Lond). 2014 Feb 04;11(1):3
pubmed: 24491080
Invest Ophthalmol. 1968 Oct;7(5):501-19
pubmed: 5693186
Mol Med Rep. 2017 Aug;16(2):1691-1700
pubmed: 28627626
Cell Biochem Biophys. 2010 May;57(1):9-17
pubmed: 20361273
Front Biosci. 2001 Oct 01;6:D1151-60
pubmed: 11578972
Acta Ophthalmol. 2014 May;92(3):e170-84
pubmed: 23819758
PLoS One. 2013 Jun 12;8(6):e66781
pubmed: 23776698
Am J Pathol. 1993 Dec;143(6):1699-712
pubmed: 8256857
Acta Ophthalmol. 2011 Jun;89(4):e315-9
pubmed: 21310014
Glia. 2007 Nov 15;55(15):1554-64
pubmed: 17823969
Jpn J Ophthalmol. 2018 Jan;62(1):92-100
pubmed: 29094325
Neurosci Lett. 2010 Dec 17;486(3):197-201
pubmed: 20869426
Invest Ophthalmol Vis Sci. 2012 Mar 02;53(3):1130-8
pubmed: 22247467
Surv Ophthalmol. 2018 Mar - Apr;63(2):214-235
pubmed: 28935121
Clin Chem. 2009 Apr;55(4):611-22
pubmed: 19246619
Nature. 2007 Aug 23;448(7156):901-7
pubmed: 17713529
PLoS One. 2014 Jan 23;9(1):e86570
pubmed: 24466155
J Cell Biol. 1998 Dec 14;143(6):1725-34
pubmed: 9852163
Ann Anat. 2017 May;211:13-20
pubmed: 28163201
Invest Ophthalmol Vis Sci. 1993 Nov;34(12):3429-41
pubmed: 7693609
Exp Eye Res. 2013 Oct;115:178-88
pubmed: 23876491
Crit Rev Biochem Mol Biol. 2016 Nov/Dec;51(6):413-439
pubmed: 27387655
Surv Ophthalmol. 1997 Jan-Feb;41(4):275-313
pubmed: 9104767
Prog Mol Biol Transl Sci. 2015;134:7-23
pubmed: 26310146
Biochim Biophys Acta. 2013 Jan;1833(1):101-9
pubmed: 23103427
Am J Transl Res. 2017 Dec 15;9(12):5181-5196
pubmed: 29312476
Neurochem Int. 2012 May;60(6):640-51
pubmed: 22417726
J Invest Dermatol. 2008 Jun;128(6):1545-53
pubmed: 18239618
Immunobiology. 1997 Dec;198(1-3):35-49
pubmed: 9442376
Dev Neurobiol. 2009 Sep 15;69(11):715-30
pubmed: 19565626
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Exp Eye Res. 2001 Sep;73(3):291-302
pubmed: 11520104
Mol Cell Biochem. 2009 Dec;332(1-2):199-205
pubmed: 19588230
Front Pharmacol. 2015 Jun 16;6:126
pubmed: 26136686
Mol Vis. 2009 Nov 05;15:2230-8
pubmed: 19907665
J Biol Chem. 1992 Jul 25;267(21):14998-5004
pubmed: 1378843
Inflamm Res. 2018 Aug;67(8):691-701
pubmed: 29796842
Exp Eye Res. 2010 Sep;91(3):326-35
pubmed: 20599432
Cell Signal. 2013 Nov;25(11):2185-97
pubmed: 23838007
Biochim Biophys Acta. 2009 Jun;1793(6):993-1007
pubmed: 19121341
Chin J Traumatol. 2017 Aug;20(4):189-193
pubmed: 28712679
Exp Biol Med (Maywood). 2001 Jul;226(7):653-64
pubmed: 11444101
Invest Ophthalmol Vis Sci. 2004 Jan;45(1):100-9
pubmed: 14691160
Vision Res. 2017 Oct;139:138-152
pubmed: 28404521
Physiol Rev. 1981 Oct;61(4):829-913
pubmed: 6270711
Invest Ophthalmol Vis Sci. 2013 Sep 27;54(9):6390-400
pubmed: 24078382
Acta Med Okayama. 2017 Dec;71(6):459-465
pubmed: 29276218
J Invest Dermatol. 2007 Mar;127(3):514-25
pubmed: 17299434
Int J Oncol. 2018 Aug;53(2):659-671
pubmed: 29845254
PLoS One. 2013 May 16;8(5):e63907
pubmed: 23696858
Int J Clin Exp Pathol. 2015 Mar 01;8(3):2719-27
pubmed: 26045777
Mol Cell Biochem. 2013 Nov;383(1-2):253-9
pubmed: 23955437
J Biol Chem. 1995 Oct 27;270(43):25752-61
pubmed: 7592757
Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3513-3518
pubmed: 28715585
Br J Ophthalmol. 1946 Jun;30(6):337-45
pubmed: 18170229
Invest Ophthalmol Vis Sci. 1997 Mar;38(3):600-9
pubmed: 9071213
Br J Pharmacol. 2016 Oct;173(19):2880-93
pubmed: 27472295
J Invest Dermatol. 2004 May;122(5):1310-20
pubmed: 15140236
J Neurosci. 2009 Feb 18;29(7):2009-21
pubmed: 19228955
Development. 2006 Sep;133(18):3629-39
pubmed: 16914489
Am J Physiol Lung Cell Mol Physiol. 2015 Dec 1;309(11):L1354-66
pubmed: 26432865
Diabetes. 1996 Jul;45 Suppl 3:S77-80
pubmed: 8674899
Cell. 1996 Feb 9;84(3):381-8
pubmed: 8608591